Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma

NCT00400894 | Unknown

• 1 other identifier: EA 4/033/06
• Study Type: observational
• Target: 750
• Locations: 0 countries
• Sites: N/A

Brief Summary

Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis of prostate cancer. We wanted to show or investigate, that:

• ANXA3 can be detected in urine after standard digital rectal examination.
• ANXA3 has better specificities than tPSA, in particular in the grey zone of PSA
• ANXA3 can help avoid unnecessary biopsies
• ANXA3 can in the long run replace PSA as a marker

Conditions

Prostate Cancer; Benign Prostatic Hyperplasia; Prostatic Intraepithelial Neoplasia

Keywords

prostate cancer; annexin A3; early detection; exprimate urine

Eligibility Criteria

• Sex: male
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with a histological confirmation of adenocarcinoma of the prostate
• Patients with benign prostatic hyperplasia (confirmed by histology of lance biopsies or TUR-P)

You may not qualify if:

• Patients with rectal extirpation
• Patients with renal or bladder tumors

Sponsors & Collaborators

• ProteoSys AG: lead
• Charite University, Berlin, Germany: collaborator
• University Hospital Tuebingen: collaborator
• Medical Centre, Ludwigshafen, Germany: collaborator
• Medical University Innsbruck: collaborator

Related Publications (2)

• Wozny W, Schroer K, Schwall GP, Poznanovic S, Stegmann W, Dietz K, Rogatsch H, Schaefer G, Huebl H, Klocker H, Schrattenholz A, Cahill MA. Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: cancer association of annexin A3. Proteomics. 2007 Jan;7(2):313-22. doi: 10.1002/pmic.200600646.

  PMID: 17205602 BACKGROUND

• Schostak M, Schwall GP, Poznanovic S, Groebe K, Muller M, Messinger D, Miller K, Krause H, Pelzer A, Horninger W, Klocker H, Hennenlotter J, Feyerabend S, Stenzl A, Schrattenholz A. Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol. 2009 Jan;181(1):343-53. doi: 10.1016/j.juro.2008.08.119. Epub 2008 Nov 13.

  PMID: 19012935 DERIVED

MeSH Terms

Conditions

Prostatic Neoplasms; Prostatic Hyperplasia; Prostatic Intraepithelial Neoplasia

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Carcinoma in Situ; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type

Study Officials

• Martin Schostak, PD Dr.

  University Medical Centre Charité, Berlin, Germany

  PRINCIPAL INVESTIGATOR

• André Schrattenholz, Prof. Dr.

  ProteoSys AG, Mainz, Germany

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: DEFINED POPULATION
• Time Perspective: OTHER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: November 16, 2006
• First Posted: November 17, 2006
• Study Start: September 1, 2005
• Study Completion: September 1, 2006
• Last Updated: February 5, 2007

Record last verified: 2007-02